Data centers are expanding at an unprecedented pace, driven by the need to build and train more AI models by the day. But here’s the shocking truth: AI-driven applications like ChatGPT consume
In 2024, Palantir Technologies has seen its stock price more than double, a remarkable run that has captured the attention of investors. Known for its cutting-edge work in artificial intelligence (AI), defense,
In the face of an evolving market landscape, investors are increasingly focusing on funds that offer growth potential, and one ETF that stands out is the Vanguard S&P 500 Growth ETF. This
What Happened UBS released its latest forecast for the US bond market, predicting the 10-year Treasury yield will rise to 4.25% by the end of 2025, with the 2-year note yield reaching
What Happened Netflix announced Tuesday it will raise prices on most of its subscription tiers in the US and Canada following a record-breaking 19 million new subscribers in Q4 2024. The streaming
What Happened Nvidia (NVDA) shares surged 4% on Wednesday after news broke that the company has been selected as the main technology partner for Stargate’s $500 billion AI infrastructure project. The partnership
What Happened The inauguration of Donald Trump as the 47th President of the United States on Monday was marked by the presence of the world’s wealthiest individuals, drawing comparisons to the annual
What Happened Brokerage firm Charles Schwab announced a 44% rise in profit for the fourth quarter, driven by a significant increase in asset management fees. The news sent Schwab’s shares up by
JPMorgan Chase Posts Record Earnings and Revenue, Setting Banking Milestones JPMorgan Chase reinforced its position as the largest and most profitable U.S. bank by reporting record quarterly and annual earnings and revenue
Eli Lilly Stock Falls 8% on Lower-than-Expected Zepbound Sales Forecast Eli Lilly’s shares dropped 8% on Tuesday after the pharmaceutical giant forecast fourth-quarter sales for its weight-loss drug Zepbound below Wall Street
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion Johnson & Johnson (J&J) announced on Monday its $14.6 billion acquisition of neurological drugmaker Intra-Cellular Therapies, marking its largest deal in over two
Blue Origin Scrubs First New Glenn Rocket Launch Due to Technical Issues Blue Origin canceled the much-anticipated debut launch of its massive New Glenn rocket early Monday due to technical problems. The
Walgreens Reports Earnings Beat Amid Store Closures and Cost Cuts Walgreens reported fiscal first-quarter results on Friday that surpassed Wall Street expectations, as the company undertakes cost-cutting measures, including the closure of